
Asimov provides scientists and manufacturers tools that simplify designing and manufacturing biologic drugs and gene therapies. The company combines mammalian synthetic biology with computer-aided design and machine learning to program living cells and optimize therapeutic candidates. Its platform uses AI-driven predictive models and CAD-style design workflows to accelerate biological design cycles for research teams, biotechs, and contract developers. Asimov operates in the B2B life sciences software and tools market focused on next-generation therapeutics.

Asimov provides scientists and manufacturers tools that simplify designing and manufacturing biologic drugs and gene therapies. The company combines mammalian synthetic biology with computer-aided design and machine learning to program living cells and optimize therapeutic candidates. Its platform uses AI-driven predictive models and CAD-style design workflows to accelerate biological design cycles for research teams, biotechs, and contract developers. Asimov operates in the B2B life sciences software and tools market focused on next-generation therapeutics.
Founded: 2017
Headquarters: Boston
Focus: Cells-to-software synthetic biology platform for designing and manufacturing biologics and cell/gene therapies
Product highlights: CHO Edge, LV Edge, AAV Edge, Kernel (genetic design software)
Funding: $205,000,000 total (latest listed: Series B on 2023-01-05)
Synthetic biology and biomanufacturing for next-generation therapeutics (biologics, cell and gene therapies).
2017
Biotechnology Research
$4.7M
Reported seed funding amount per press coverage.
“Backed by institutional investors including Andreessen Horowitz, CPP Investments, Horizons Ventures, Fidelity Management & Research Company, Casdin Capital, DCVC, AME Cloud Ventures, KdT Ventures, and Pillar VC.”
| Company |
|---|
Our mission at Asimov is to radically advance humankind's ability to design living systems, enabling biotechnologies with societal benefit. We're developing a mammalian synthetic biology platform––from cells to software––to enable biotechnologies with outsized impact, with an initial focus on gene therapies, cell therapies, and protein therapeutics.
We are seeking a strategic, hands-on Head of Finance to build and lead our finance and accounting function from the ground up. In this newly created role, and reporting to the Head of Commercial, you will establish core financial processes, ensure accurate revenue recognition, support budgeting and forecasting, while overseeing all accounts payable and receivable activities.
This role offers the unique opportunity to design and optimize financial systems as a team of one within a rapidly growing biotech startup. The ideal candidate will thrive in a fast paced, collaborative environment while bringing financial rigor, process discipline, and forward-thinking leadership needed to support scientific innovation and fuel the company’s next phase of growth.
About The Role
About You
We’re fueled by a vision to transform biological engineering into a fully-fledged engineering discipline. Should you join our team, you will grow with a constantly evolving organization and push the frontiers of synthetic biology. Company culture is key to Asimov, and we believe that our mission can only be achieved by bringing together a diverse team with a mixture of backgrounds and perspectives.
Compensation Range: $170K - $200K